Veeva Systems

Veeva Systems is an American company headquartered in Pleasanton, California that provides cloud software, data, and consulting services for the life sciences industry.^[2] Its applications are used to manage drug development, regulatory affairs, quality, safety, medical affairs, and commercial operations, and the company states that 85 percent of new drugs approved in recent years were launched using its platform.^[1][2][6].

Founded in 2007 by Peter Gassner and Matt Wallach, Veeva became a public company on the New York Stock Exchange in October 2013 and in February 2021 became the first publicly traded company to convert to a public benefit corporation.^[2] In its fiscal year 2026 it reported revenue of US$3.195 billion and approximately 7,900 employees, serving more than 1,500 customers including most of the largest global pharmaceutical companies.^[2]

What It Does

Veeva positions itself as the industry cloud for life sciences, offering applications, AI agents, data, and business consulting across research and development, quality, and commercial functions. Its software tracks all aspects of drug development and pharmaceutical manufacturing, from clinical trial management through regulatory submissions to field engagement with healthcare professionals.^[1][2]

The company's current strategy centers on agentic artificial intelligence: Vault AI embeds agents into its core platform, while Veeva Falcon delivers what the company calls agentic labor for clinical intake, regulatory authoring, safety triage, and marketing content review.^[1]

Products

- Veeva Clinical Platform — electronic trial master file, CTMS, EDC, eCOA, payments, study startup, and randomization and trial supply management on a single system of record.^[1]

- Veeva RIM — regulatory information management spanning registrations, submissions, publishing, and archives.^[1]

- Veeva Quality Cloud — QMS, controlled documents, LIMS, training, validation management, and batch release.^[1]

- Veeva Safety Suite — adverse event management, signal detection, and pharmacovigilance operations.^[1]

- CRM Suite and Commercial Evidence — customer relationship management built natively on the Vault Platform, with AI-generated call reports that surface treatment barriers for field teams.^[1]

- Veeva Data Cloud — OpenData reference profiles of healthcare professionals and organizations, HCP access data, Veeva Link key people and key accounts intelligence, and Compass patient, prescriber, and national projected performance data for the United States.^[1]

- SiteVault — free-to-site solutions for research sites covering eISF, eConsent, eSource, and site CTMS.^[1]

Data and Methodology

Veeva's data assets combine proprietary reference data on healthcare professionals and organizations with patient-level analytics acquired through Crossix, a privacy-safe patient data and analytics specialist purchased in 2019. The Compass product line projects prescriber and national market metrics from anonymized longitudinal patient data.^[1][2]

Commercial Evidence extends this approach by transforming field and digital interactions into structured insights: according to the company, an analysis of Agentic Call Reports found that 65 percent revealed actionable treatment barriers, and customers report a sevenfold increase in high-value actions on brand sites when using its AI-powered engagement tools.^[1]

Delivery and Pricing

All products run on the multitenant Veeva Vault Platform or the CRM Suite delivered as subscription cloud services, complemented by business consulting, analytics advisory, education services, and a partner ecosystem of systems integrators, CROs, and data providers. Pricing follows enterprise subscriptions scoped by product and user population and is not published publicly.^[1]

As a public benefit corporation, Veeva states that it weighs the interests of customers, employees, shareholders, and communities in its decisions, a status it adopted in 2021 as the first publicly traded company to do so.^[1][2]

Buyers and Use Cases

Customers include Bayer, Boehringer Ingelheim, Eli Lilly and Company, Gilead Sciences, Merck & Co., Novartis, Bristol Myers Squibb, Sanofi, Daiichi Sankyo, Genentech, UCB, and Corcept Therapeutics, among more than 1,500 organizations overall.^[1][2]

Representative deployments include Sanofi consolidating forty legacy quality systems into one unified quality management system, Merck connecting clinical data directly into its safety database, Boehringer Ingelheim accelerating clinical trials on the unified clinical platform, and Bristol Myers Squibb and Eli Lilly committing to Vault CRM for commercial operations.^[1][2]

History

Peter Gassner, previously a salesforce.com executive, and Matt Wallach founded Veeva in 2007 to bring cloud software to pharmaceutical commercial teams. In February 2011 the company introduced Veeva Vault, a regulated content management system that became the foundation for its later application suites.^[2]

The company went public on the New York Stock Exchange under ticker VEEV in October 2013, with shares nearly doubling in their debut.^[2][3] It subsequently expanded through acquisitions including Zinc Ahead in 2015 for content management, Crossix in 2019 for patient data analytics, Physicians World in 2019, Learnaboutgmp in 2021, Veracity Logic in 2021 for randomization and trial supply software, and Ostro in March 2026 for US$100 million, adding an AI chat tool for pharma brand engagement alongside Copli, which seeded the Falcon MLR agent.^[1][2][4]

In January 2021 Veeva announced its conversion to a public benefit corporation, completed the following month.^[2] In 2025 the company ended its long-standing technology partnership with Salesforce, which had begun competing in life sciences CRM, and completed the migration of its CRM Suite onto its own Vault Platform.^[2][5]